Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bonora

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
HIV Medicine|May 31, 2018
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparisonL Taramasso, A Di Biagio, F Maggiolo, et al.
HIV Medicine|November 22, 2018
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014A d'Arminio Monforte, H Diaz-Cuervo, A De Luca, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 7, 2015
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studyS Nozza, L Galli, A Antinori, et al.
Infection|May 28, 2009
Efficacy and safety of atazanavir in patients with end-stage liver diseaseG Guaraldi, S Cocchi, A Motta, et al.
Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 29, 2019
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patientsR Ungaro, L Taramasso, B Bruzzone, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2013
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal functionA Calcagno, D Gonzalez de Requena, M Simiele, et al.
The Journal of Antimicrobial Chemotherapy|February 2, 2008
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferonD Aguilar Marucco, D Gonzalez de Requena, S Bonora, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2018
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIVA Borghetti, A Calcagno, F Lombardi, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimenD Armenia, D Di Carlo, A Calcagno, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
HIV Medicine|May 31, 2018
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparisonL Taramasso, A Di Biagio, F Maggiolo, et al.
HIV Medicine|November 22, 2018
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014A d'Arminio Monforte, H Diaz-Cuervo, A De Luca, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 7, 2015
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studyS Nozza, L Galli, A Antinori, et al.
Infection|May 28, 2009
Efficacy and safety of atazanavir in patients with end-stage liver diseaseG Guaraldi, S Cocchi, A Motta, et al.
Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 29, 2019
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patientsR Ungaro, L Taramasso, B Bruzzone, et al.
Antimicrobial Agents and Chemotherapy|February 6, 2013
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal functionA Calcagno, D Gonzalez de Requena, M Simiele, et al.
The Journal of Antimicrobial Chemotherapy|February 2, 2008
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferonD Aguilar Marucco, D Gonzalez de Requena, S Bonora, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2018
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIVA Borghetti, A Calcagno, F Lombardi, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimenD Armenia, D Di Carlo, A Calcagno, et al.
Pageof 11